Product apis-pi3k-akt-mtor

Home > products > apis> pi3k-akt-mtor

Catalog	name	Description	price
R-R-1150	Afuresertib hydrochloride CAS No.1047645-82-8	Afuresertib hydrochloride (GSK 2110183 hydrochloride)/CAS No.1047645-82-8 is an orally bioavailable, selective, ATP-competitive and potent pan-Akt kinase inhibitor with Kis of 0.08/2/2.6 nM for Akt1/Akt2/Akt3 respectively.	price>
R-R-1151	Cenisertib CAS No.871357-89-0	Cenisertib (AS-703569)/CAS No.871357-89-0 is an ATP-competitive multi-kinase inhibitor that blocks the activity of Aurora-kinase-A/B, ABL1, AKT, STAT5 and FLT3. Cenisertib induces major growth-inhibitory effects by blocking the activity of several different molecular targets in neoplastic mast cells (MC). Cenisertib inhibits tumor growth in xenograft models of pancreatic, breast, colon, ovarian, and lung tumors and leukemia.	price>
R-R-1152	PI3K/AKT-IN-1	PI3K/AKT-IN-1 is an effective PI3K/AKT dual inhibitor (IC50 of 6.99, 4.01 and 3.36 μM for PI3Kγ, PI3Kδ and AKT, respectively). PI3K/AKT-IN-1 has anticancer activity and acts by inhibiting PI3K/AKT axis and inducing caspase 3 dependent apoptosis.	price>
R-R-1153	3CAI CAS No.28755-03-5	3CAI/CAS No.28755-03-5 is a potent and specific AKT1 and AKT2 inhibitor.	price>
R-R-1154	INY-03-041 CAS No.2503017-97-6	INY-03-041/CAS No.2503017-97-6 is a potent, highly selective and PROTAC-based pan-AKT degrader consisting of the ATP-competitive AKT inhibitor Ipatasertib (HY-15186) conjugated to Lenalidomide (HY-A0003, Cereblon ligand). INY-03-041 inhibits AKT1, AKT2 and AKT3 with IC50s of 2.0, 6.8 and 3.5 nM, respectively.	price>
R-R-1155	KP372-1 CAS No.1374996-60-7	KP372-1/CAS No.1374996-60-7 is an Akt inhibitor that inhibits proliferation and induces apoptosis and anoikis. KP372-1 is also an NQO1 redox cycling agent that causes DNA damage (including DNA breakage) by generating ROS. KP372-1 can be used in cancer research (such as head and neck squamous cell carcinoma (HNSCC) and pancreatic cancer).	price>
R-R-1156	SEW2871 CAS No.256414-75-2	SEW2871/CAS No.256414-75-2 is an orally active, potent, highly selective S1P1 (sphingosine-1-phosphate type 1 receptor) agonist, with an EC50 of 13.8 nM. SEW2871 activates ERK, Akt, and Rac signaling pathways and induces S1P1 internalization and recycling. SEW2871 reduces lymphocyte numbers in blood.	price>
R-R-1157	PI3K/Akt/CREB activator 1 CAS No.2708177-73-3	PI3K/Akt/CREB activator 1 (compound AE-18)/CAS No.2708177-73-3 is a potent, orally active PI3K/Akt/CREB activator. PI3K/Akt/CREB activator 1 promotes neuronal proliferation, induced differentiation of Neuro-2a cells into a neuron-like morphology, and accelerated the establishment of axon-dendrite polarization of primary hippocampal neurons through upregulating brain-derived neurotrophic factor via the PI3K/Akt/CREB pathway. PI3K/Akt/CREB activator 1 can be used in research of vascular dementia (VaD).	price>
R-R-1158	Pachymic acid CAS No.29070-92-6	Pachymic acid/CAS No.29070-92-6 is a lanostrane-type triterpenoid from P. cocos. Pachymic acid inhibits Akt and ERK signaling pathways.	price>
R-R-1159	Vevorisertib trihydrochloride CAS No.1416775-08-0	Vevorisertib (ARQ 751) trihydrochloride/CAS No.1416775-08-0 is a selective, allosteric, pan-AKT and AKT1-E17K mutant inhibitors. Vevorisertib trihydrochloride potently inhibit phosphorylation of AKT. Vevorisertib trihydrochloride has Kd values of 1.2 nM and 8.6 nM for AKT1 and AKT1-E17K, respectively. Vevorisertib trihydrochloride has IC50 values of 0.55, 0.81, and 1.3 nM for AKT1, AKT2, and AKT3, respectively. Vevorisertib trihydrochloride can be used for the research of cancer.	price>

...